Follow-On Biologics Debate Creates Strange Bedfellows As Bills Emerge
Executive Summary
Sen. David Vitter's strange bedfellows might help Democrats pick up his seat in 2010, but for now, they are hoping that his unusual alliances will help them advance healthcare reform
You may also be interested in...
FTC’s Low Blow On FOBs
FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.
Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options
The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.